S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
Log in
NYSE:DGX

Quest Diagnostics Stock Forecast, Price & News

$125.12
-0.87 (-0.69 %)
(As of 01/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$124.50
Now: $125.12
$127.39
50-Day Range
$118.33
MA: $122.55
$127.36
52-Week Range
$73.02
Now: $125.12
$131.81
Volume2.27 million shs
Average Volume1.48 million shs
Market Capitalization$16.86 billion
P/E Ratio15.47
Dividend Yield1.78%
Beta1.07
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated has a strategic collaboration with hc1; and strategic relationships with Clinical Genomics Pty Ltd and Anthem Inc. The company was founded in 1967 and is headquartered in Secaucus, New Jersey.
Quest Diagnostics logo

MarketRank

Overall MarketRank

1.91 out of 5 stars

Medical Sector

83rd out of 1,926 stocks

Medical Laboratories Industry

3rd out of 39 stocks

Analyst Opinion: 1.2Community Rank: 1.7Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
CUSIP74834L10
Phone973-520-2700
Employees47,000
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.73 billion
Cash Flow$9.07 per share
Book Value$42.22 per share

Profitability

Net Income$858 million

Miscellaneous

Market Cap$16.86 billion
Next Earnings Date2/4/2021 (Confirmed)
OptionableOptionable
$125.12
-0.87 (-0.69 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

How has Quest Diagnostics' stock been impacted by COVID-19?

Quest Diagnostics' stock was trading at $99.73 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DGX shares have increased by 25.5% and is now trading at $125.12.
View which stocks have been most impacted by COVID-19
.

Is Quest Diagnostics a buy right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last twelve months. There are currently 10 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Quest Diagnostics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DGX, but not buy additional shares or sell existing shares.
View analyst ratings for Quest Diagnostics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Quest Diagnostics?

Wall Street analysts have given Quest Diagnostics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Quest Diagnostics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Steve Rusckowski's approval rating as Quest Diagnostics' CEO?

1,053 employees have rated Quest Diagnostics CEO Steve Rusckowski on Glassdoor.com. Steve Rusckowski has an approval rating of 78% among Quest Diagnostics' employees.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Quest Diagnostics
.

How can I listen to Quest Diagnostics' earnings call?

Quest Diagnostics will be holding an earnings conference call on Thursday, February 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) announced its quarterly earnings results on Thursday, October, 22nd. The medical research company reported $4.31 EPS for the quarter, topping the Zacks' consensus estimate of $3.75 by $0.56. The medical research company had revenue of $2.79 billion for the quarter, compared to the consensus estimate of $2.71 billion. Quest Diagnostics had a trailing twelve-month return on equity of 19.23% and a net margin of 13.22%. Quest Diagnostics's quarterly revenue was up 42.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.76 earnings per share.
View Quest Diagnostics' earnings history
.

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics declared a quarterly dividend on Wednesday, November 18th. Shareholders of record on Wednesday, January 20th will be paid a dividend of $0.56 per share on Wednesday, February 3rd. This represents a $2.24 annualized dividend and a dividend yield of 1.79%. The ex-dividend date is Tuesday, January 19th.
View Quest Diagnostics' dividend history
.

Is Quest Diagnostics a good dividend stock?

Quest Diagnostics pays an annual dividend of $2.24 per share and currently has a dividend yield of 1.78%. Quest Diagnostics does not yet have a strock track record of dividend growth. The dividend payout ratio of Quest Diagnostics is 34.15%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 21.03% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.
View Quest Diagnostics' dividend history.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics issued an update on its FY20 earnings guidance on Wednesday, December, 16th. The company provided earnings per share guidance of at least $10.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $9.90. The company issued revenue guidance of at least 9.35 billion, compared to the consensus revenue estimate of $9.08 billion.

What price target have analysts set for DGX?

17 brokers have issued 12-month target prices for Quest Diagnostics' stock. Their forecasts range from $99.00 to $151.00. On average, they expect Quest Diagnostics' stock price to reach $126.65 in the next twelve months. This suggests a possible upside of 1.2% from the stock's current price.
View analysts' price targets for Quest Diagnostics
or view Wall Street analyst' top-rated stocks.

Who are some of Quest Diagnostics' key competitors?

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), Abbott Laboratories (ABT), NVIDIA (NVDA), Intel (INTC) and Cisco Systems (CSCO).

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the following people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 64, Pay $2.73M)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 59)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 58, Pay $1.03M)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 46, Pay $976.36k)
  • Mr. Manuel O. Méndez, Sr. VP & Chief Commercial Officer (Age 53, Pay $1.43M)
  • Mr. Michael J. Deppe, VP, Corp. Controller & Chief Accounting Officer (Age 54)
  • Ms. Gabrielle Wolfson, Sr. VP and Chief Information & Digital Officer
  • Mr. Shawn C. Bevec, VP of Investor Relation
  • Mr. Michael E. Prevoznik, Sr. VP & Gen. Counsel (Age 59)
  • Mr. Timothy Sharpe, VP of Compliance

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Scharf Investments LLC (0.48%), Retirement Systems of Alabama (0.16%), Coho Partners Ltd. (0.14%), New York State Teachers Retirement System (0.13%), DNB Asset Management AS (0.11%) and Copeland Capital Management LLC (0.09%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Daniel Stanzione, Everett Cunningham, Gail R Wilensky, J E Davis, Manner Carrie Eglinton, Mark Guinan, Michael E Prevoznik, Michael J Deppe and Stephen H Rusckowski.
View institutional ownership trends for Quest Diagnostics
.

Which major investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including Sabal Trust CO, Retirement Systems of Alabama, DNB Asset Management AS, Scharf Investments LLC, Crossmark Global Holdings Inc., Cypress Capital Group, CHURCHILL MANAGEMENT Corp, and Calamos Advisors LLC. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Daniel Stanzione, J E Davis, Manner Carrie Eglinton, Mark Guinan, Michael E Prevoznik, Michael J Deppe, and Stephen H Rusckowski.
View insider buying and selling activity for Quest Diagnostics
or view top insider-selling stocks.

Which major investors are buying Quest Diagnostics stock?

DGX stock was purchased by a variety of institutional investors in the last quarter, including Keeler Thomas Management LLC, Candriam Luxembourg S.C.A., Kestra Advisory Services LLC, Coho Partners Ltd., Pacer Advisors Inc., Cascade Investment Advisors Inc., Pendal Group Limited, and Exane Derivatives.
View insider buying and selling activity for Quest Diagnostics
or or view top insider-buying stocks.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $125.12.

How big of a company is Quest Diagnostics?

Quest Diagnostics has a market capitalization of $16.86 billion and generates $7.73 billion in revenue each year. The medical research company earns $858 million in net income (profit) each year or $6.56 on an earnings per share basis. Quest Diagnostics employs 47,000 workers across the globe.

What is Quest Diagnostics' official website?

The official website for Quest Diagnostics is www.questdiagnostics.com.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.